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Abstract
Background—Clinicians can miss up to half of patients’ symptomatic toxicities in cancer 
clinical trials and routine practice. Although patient-reported outcome questionnaires have been 
developed to capture this information, it is unclear whether clinicians will make use of patient-
reported outcomes to inform their own toxicity documentation, or to prompt symptom 
management activities.
Methods—44 lung cancer patients that participated in a phase 2 treatment trial self-reported 13 
symptomatic toxicities derived from the National Cancer Institute’s Common Terminology 
Criteria for Adverse Events and Karnofsky Performance Status via tablet computers in waiting 
areas immediately preceding scheduled visits. During visits, clinicians viewed patients’ self-
reported toxicity and performance status ratings on a computer interface and could agree or 
disagree/reassign grades (“shared” reporting). Agreement of clinicians with patient-reported 
grades was tabulated, and compared using weighted kappa statistics. Clinical actions in response 
to patient-reported severe (grade 3/4) toxicities were measured (e.g. treatment discontinuation, 
dose reduction, supportive medications). For comparison, 45 non-trial patients with lung cancer 
being treated in the same clinic by the same physicians were simultaneously enrolled in a parallel 
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cohort study in which patients also self-reported toxicity grades but reports were not shared with 
clinicians (“non-shared” reporting).
Results—Toxicities and performance status were reported by patients and reviewed by clinicians 
at (780/782) 99.7% of study visits in the phase 2 trial which used “shared” reporting. Clinicians 
agreed with patients 93% of the time with kappas 0.82–0.92. Clinical actions were taken in 
response to 67% of severe patient-reported toxicities. In the “non-shared” reporting comparison 
group, clinicians agreed with patients 56% of the time with kappas 0.04–0.48 (significantly worse 
than shared reporting for all symptoms), and clinical actions were taken in response to 44% of 
severe patient-reported toxicities.
Conclusion—Clinicians will frequently agree with patient-reported symptoms and performance 
status, and will use this information to guide documentation and symptom management. 
(ClinicalTrials.gov: NCT00807573).
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Introduction
Symptomatic toxicities such as nausea or sensory neuropathy and performance status 
impairments are common during cancer treatment.1,2 Capturing information about these 
patient experiences is an essential component of clinical research and of treatment 
management. The current standard approach for capturing this information in clinical trials 
involves research staff eliciting and documenting patients’ toxicities using items from the 
National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAE),3 
and performance status using standardized questions such as Karnofsky Performance Status 
(KPS).4 However, this approach, which does not involve systematic patient self-reporting, 
has been found to miss up to half of patients’ symptoms and functional limitations5–9 and to 
have low levels of inter-rater reliability.10 The ultimate consequence of this low recognition 
is underestimation of treatment toxicities and potentially inappropriate clinical management 
for ailing patients.11
Patient self-reporting has been proposed as an approach to improve the accuracy of symptom 
and performance status monitoring in trials, and has been found to be reliable, feasible, and 
valued by patients and clinicians.12–20 There are ongoing efforts to develop a patient-
reported outcomes extension of the CTCAE called the PRO-CTCAE.21 However, there are 
several basic unanswered questions related to implementation of patient-reported toxicities 
and performance status in trials. First, given that patient and clinician reporting is discrepant, 
how might we reconcile this discrepancy in a given clinical trial when both patients and 
clinicians are reporting on the same domains? Second, will clinicians agree with the reports 
of their patients? And third, will clinicians find the patient-reported information to be 
actionable (e.g. useful as a basis to prompt treatment changes)?
To address these questions, we designed a pilot study in which patients enrolled in a phase 2 
clinical trial and self-reported symptomatic toxicities from the CTCAE and KPS using 
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previously developed and tested items.8,18,22 This information was conveyed electronically 
to clinicians who could either agree or disagree with the patients’ grades as an approach to 
reconciliation at the point of care.
Methods
Patients and procedures
All patients enrolling on a previously reported23 phase 2 trial at the Memorial Sloan 
Kettering Cancer Center evaluating paclitaxel plus pemetrexed and bevacizumab in 
untreated advanced non-small cell lung cancers, also participated in this patient-reported 
outcomes correlative study. All participants signed an informed consent document for this 
Institutional Review Board-approved study (ClinicalTrials.gov: NCT00807573). Treatment 
was continued until progressive disease or unacceptable toxicity.
At baseline and at each subsequent medical visit, participants were provided with a wireless 
tablet computer in the waiting area prior to the clinical encounter, via which they self-
reported 13 symptomatic toxicities using previously developed and tested patient versions of 
the CTCAE and KPS,18 and a previously described patient software interface.22 The 13 
symptomatic toxicities included alopecia, anorexia, cough, dyspnea, epiphora, epistaxis, 
fatigue, hoarseness, mucositis, myalgia, nausea, pain, and sensory neuropathy. CTCAE 
items representing individual toxicities are graded on a five-point ordinal scale anchored to 
discrete clinical criteria with higher numbers being worse and grades 3 and 4 generally 
indicating a need for clinical action.3 KPS is graded using an 11-point ordinal percentage 
scale separated by 10-point increments (e.g. 10%, 20%, 30% … 100%) with higher numbers 
being better.4
The patient-assigned grades were transmitted to a practitioner software interface that 
allowed clinicians to view the patient-assigned grades and either agree or reassign any 
grades in real-time (“shared” reporting) (Figure 1). The practitioner interface was accessed 
by research nurses via their own tablet computers during visits, following which attending 
oncologist physician investigators accessed it to view both the patient- and nurse-assigned 
grades, with an opportunity to further modify the grades before digitally locking them for 
submission to the institutional clinical research database. The final investigator-locked 
grades were used as the definitive adverse event documentation for the trial.
For comparison, a parallel cohort study was conducted simultaneously with the phase 2 trial 
to which individuals with similar eligibility being treated in the same clinic by the same 
physicians but who were not enrolled in the clinical trial were enrolled. In this comparison 
study, a smaller subset of six CTCAE symptomatic toxicities plus KPS were self-reported by 
patients at clinic visits via tablet computers, but reports were not shared with research nurses 
or oncologists (“non-shared” reporting). The measured symptoms included anorexia, cough, 
dyspnea, fatigue, nausea, and pain. These patients received treatment at the discretion of 
their physicians. This research component was also Institutional Review Board-approved 
and patients underwent informed consent. Clinical staff similarly documented symptomatic 
toxicities using CTCAE grades, but without access to patient self-reports.
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Outcomes
For both, the phase 2 trial (“shared” reporting) group and the comparison study (“non-
shared” reporting) group, the proportion of patients and clinicians agreeing and disagreeing 
on each CTCAE symptomatic toxicity and KPS was tabulated. The primary comparison was 
conducted at the third scheduled clinic visit for each patient, and as sensitivity analyses were 
tabulated at the fifth visit and also by aggregating all CTCAE data across six visits. 
Clinicians’ actions taken on days when patients self-reported severe (grade 3 or 4) events 
were tracked via chart abstraction. Clinical actions were categorized based on prior 
research24 as: no action; holding chemotherapy for that visit; discontinuing treatment; dose-
reducing chemotherapy; referring to a subspecialty service; referring for imaging; 
prescribing supportive medication; increasing analgesic dose; sending to emergency room; 
and ordering a blood transfusion. In the shared reporting group, rates of clinician agreement, 
upgrading, and downgrading at each level of patient grade and for each symptom were 
calculated. A brief paper questionnaire was administered to clinicians caring for patients in 
the clinical trial after 6 months of participation, based on feasibility assessments used in 
prior similar research,18 to assess ease of use and satisfaction with the shared reporting 
system.
Statistical analysis
For both the phase 2 trial (“shared” reporting) group and the comparison study (“non-
shared” reporting) group, clinician agreement with patient reports was evaluated for each 
symptomatic toxicity and overall. We calculated the proportion of patient-clinician symptom 
pairs for which an identical grade was assigned by patient and clinician, and the proportion 
of pairs where the clinicians graded lower (downgraded) and graded higher (upgraded). The 
level of agreement between patients and clinicians for each symptom and KPS was 
estimated for the shared and non-shared reporting groups with a weighted kappa statistic.15 
A kappa value less than 0.4 is generally considered as poor agreement; 0.4–0.75 is 
considered as fair-to-good agreement; and 0.75 or more is considered as excellent 
agreement. In addition, the level of agreement for each symptom was compared between 
groups using a chi-square statistic. Clinical actions taken in response to severe (grade 3 or 4) 
toxicities were tabulated descriptively for each group.
Results
Baseline characteristics of patients enrolled in the phase 2 trial (shared reporting group; N = 
44) and in the comparison (non-shared reporting group; N = 45) are shown in Table 1. 
Participants were similar in sex, age, race, and baseline performance status.
Figure 2 shows the proportion of patient-clinician pairs in each group with agreement and 
disagreement for the six CTCAE symptoms reported in both groups and for KPS. In the 
shared reporting group, overall agreement of clinician-reported grades with patient-reported 
grades was 93%, with agreement for specific symptoms and KPS ranging from 84%–96%. 
This magnitude of agreement was observed across all 13 assessed symptoms. In contrast, in 
the non-shared reporting group, overall agreement was lower at 56%, ranging for various 
symptoms from 51%–72%. Results were similar in the planned sensitivity analyses. In both 
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groups, in cases of discrepant grading between patients and clinicians, 82% of the time the 
discrepancy was by 1 grade point on the CTCAE scale, and in 18% by 2 or more points.
A comparison of levels of agreement between clinician-patient pairs in the shared and non-
shared reporting groups is shown Table 2. For the shared reporting group, weighted kappas 
ranged from 0.82–0.92, indicating excellent agreement, whereas for the non-shared group, 
kappas ranged from 0.04–0.48, indicating generally poor agreement. Weighted kappas were 
statistically significantly higher in the shared group than in the non-shared group for all 
symptoms with all p < 0.01.
In the shared reporting group, for the 7% of cases when clinicians did not agree with patients 
(i.e. 685 of the 9610 patient-reported toxicities), rates of agreement varied depending on the 
initial grade level reported by patients (Table 3). There was greater disagreement at higher 
grade levels, with more downgrading by clinicians than upgrading. When considering Grade 
3 toxicities specifically, most of the patient-reported events consisted of fatigue, pain, and 
dyspnea (accounting for 104/168 (62%) of reported toxicities), and the majority of these 
were downgraded by clinicians (eTable 1; online only).
Clinical actions taken concomitantly with patient-reported severe (grade 3 or 4) toxicities are 
shown in eTable 2 (online only). In the shared rating group, 126/187 (67%) of patient-
reported severe toxicities were associated with clinical actions. In the non-shared group, 
22/51 (44%) of patient-reported severe toxicities were associated with clinical actions. In 
both groups, the most frequent severe toxicities were fatigue, pain, and dyspnea; the most 
frequent clinical actions were treatment-held and supportive medications prescribed.
In a paper questionnaire administered to the 12 clinicians caring for patients enrolled in the 
clinical trial (four physicians and eight research nurses), the amount of time to electronically 
retrieve and reassign patient-reported grades at any visit was reported as 2 min (range, 1–6); 
all respondents (12/12; 100%) felt the software was easy to use, intuitive, and they would 
feel comfortable using it in future studies; 10/12 (83%) used the system to aid their toxicity 
assessments during the trial although fewer (4/11; 36%) felt they used the system regularly 
to make clinical decisions.
Discussion
In this pilot study, an electronic system for sharing patient-reported symptoms with 
clinicians in real-time was feasible to implement in a phase 2 clinical trial, with virtually all 
patients and clinicians completing symptom reports and reviews at the point of care. 
Moreover, clinicians made use of this information to inform their own symptom 
assessments, documentation, and symptom management activities. Prior research has 
reported that clinicians under-detect symptoms.5–9 This study provides evidence that this 
under-detection may be substantially alleviated by sharing patient reports with clinicians as a 
standard part of the symptom assessment and documentation workflow.
Agreement between patients and clinicians was 93% when patient reports were shared at 
appointments, which was improved compared to the non-shared comparison group (and to 
historical comparisons7,8), where overall agreement was 56%. Although this represents 
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substantial and improved agreement, levels of agreement notably diminished as the severity 
of patient-reported toxicities rose. While it was rare for a clinician to disagree with a patient-
reported grade of 0 (no symptom) or 1 (mild), clinicians more frequently downgraded grade 
2 and 3 patient-reported toxicities. Moreover, while it was unusual for a clinician to upgrade 
a patient’s grade 2 up to a grade 3, it was more common for a clinician to downgrade a 3 to a 
2.
The reasons for clinician downgrades of grade 3 toxicities may be related to clinicians’ 
preferences not to hold or dose-reduce chemotherapy treatments for patients enrolled in the 
trial, which was required in the protocol for any documented grade 3 toxicity. Despite this 
potential inclination, clinicians nonetheless agreed with patient-reported grade 3 toxicities 
about a third of the time. Another potential reason for clinician downgrades is that the 
patient questionnaire used in this study was an early patient adaptation of the CTCAE22 
which was subsequently substantially revised and validated under contract to the National 
Cancer Institute.21 A particular limitation of the grade 3 designations in the questionnaire 
version used in this study was inclusion of clinical criteria such as need for an intervention 
(e.g. intravenous fluids), which a patient may not be in the best position to answer. The new 
version, the PRO-CTCAE,21 includes no such criteria and was rigorously developed and 
tested with patient and clinician input. Notably, there is an ongoing multicenter cooperative 
group trial comparing shared versus non-shared reporting using the PRO-CTCAE. 
Regardless, this finding suggests that although sharing patient reports can enhance clinician 
reporting, for analysis purposes, patient self-reports may be considered in their unadulterated 
forms as a reflection of the unfiltered patient experience.
There are several additional limitations of this study, including its conduct in a single center 
and use of a non-randomized comparison. Although the comparison groups appeared similar 
at baseline, their subsequent experiences with treatment likely differed, underlined by the 
observation that during a similar reporting period, there were 187 severe (≥grade 3) 
symptomatic toxicities reported in the clinical trial population compared to 51 in the non-
clinical trial population. The differences between groups are inherent limitations of a pilot 
study, which are being addressed in an ongoing follow-up cooperative group study that 
includes randomization to reporting or not.
In conclusion, this study provides compelling evidence that a shared reporting approach 
brings clinician perception and documentation into greater alignment with the patient 
perspective. This approach not only has implications for research conduct, but also for 
enhancing symptom management and communication. With proliferation of electronic 
health records and patient portals, it is likely that patients will increasingly be asked to report 
their own health status.25 This study provides a preview of how that information might be 
electronically integrated into clinical workflow.
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Figure 1. 
Clinical trial web interface via which clinicians can review and agree or modify patient-
reported CTCAE and KPS ratings in real-time.
CTCAE: Common Terminology Criteria for Adverse Events; KPS: Karnofsky Performance 
Status.
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Figure 2. 
(a) Agreement between patient and clinician CTCAE and KPS ratings when patient-reported 
adverse events are shared with clinicians in real-time at the point of care (“shared” 
reporting) and (b) agreement between patient and clinician CTCAE and KPS ratings when 
patient-reported adverse events are not shared with clinicians (“non-shared” reporting).
CTCAE: Common Terminology Criteria for Adverse Events; KPS: Karnofsky Performance 
Status.
Note: Levels of agreement for additional measured symptoms were similar with the shown 
symptoms, including alopecia (89%); epiphora (88%); epistaxis (95%); mucositis (89%); 
myalgia (79%); sensory neuropathy (98%); and voice changes/hoarseness (91%).
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Table 1
Baseline characteristics of the patient participants.
Patient attributes Phase 2 trial group
(Shared CTCAE/KPS Reporting)
(N = 44)
Comparison group
(Non-shared CTCAE/KPS reporting)
(N = 45)
Sex
 Female 22 (50%) 21 (47%)
Age
 Median (range) 59 (31–77) 59 (38–76)
 >70   3 (7%)   2 (4%)
 50–70 35 (80%) 33 (73%)
 <50   7 (16%) 10 (22%)
Race
 Caucasian 41 (93%) 38 (84%)
 African-American   0 (0%)   4 (9%)
 Other   3 (7%)   3 (7%)
Baseline KPS
 ≥90 19 (43%) 17 (38%)
 80 20 (45%) 23 (51%)
 70   5 (11%)   5 (11%)
 ≤60   0 (0%)   0 (0%)
CTCAE: Common Terminology Criteria for Adverse Events; KPS: Karnofsky Performance Status.
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Table 2
Agreement between patients and clinicians in their toxicity and performance status ratings at cycle 3 of 
treatment, comparing shared reporting (patient reports shared with clinicians at point of care) versus non-
shared reporting (patient reports not shared with clinicians).
Weighted kappa values
Shared reporting Non-shared reporting p value
Pain 0.82 0.39   0.001
Nausea 0.91 0.48 <0.001
Fatigue 0.84 0.04 <0.001
Dyspnea 0.91 0.38 <0.001
Cough 0.92 0.36   0.002
Anorexia 0.9 0.21 <0.001
KPS 0.83 0.24 <0.001
KPS: Karnofsky Performance Status.
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Table 3
Rates of clinician agreement with patient-reported symptomatic toxicities, by grade level of patient reports, 
when patient-reported toxicities were shared with clinicians in a phase 2 clinical trial (N = 44).
Patient-reported grade level Total # reported by 
patients
Clinician agreed # (%) Clinician upgraded # 
(%)
Clinician downgraded # 
(%)
Grade 0 6158 6000 (97%) 152 (2%) Not applicable
Grade 1 2553 2407 (94%) 94 (3.5%)   49 (2%)
Grade 2   731   471 (64%) 4 (<1%) 253 (35%)
Grade 3   168     47 (28%) Not applicable 121 (72%)
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